Barclays controversies examined in Renting Rubin through Daniel Rubin’s secondment and the company’s regulatory record
Daniel Rubin Horsfield Menzies, Horsfield Menzies, Renting Rubin

Renting Rubin : AstraZeneca III – The $400 Billion Adverse Reaction

The first AstraZeneca instalment examined its reputation-management placebo. Part II followed the company’s “patients first” rhetoric to the public purse.